Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.01 USD | +3.45% | -4.88% | -21.04% |
Mar. 01 | Ibex Insider Sold Shares Worth $250,873, According to a Recent SEC Filing | MT |
Feb. 08 | Transcript : IBEX Limited, Q2 2024 Earnings Call, Feb 08, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Its low valuation, with P/E ratio at 8.25 and 7.86 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The stock, which is currently worth 2024 to 0.38 times its sales, is clearly overvalued in comparison with peers.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.04% | 264M | C | ||
-15.36% | 226B | B | ||
-0.70% | 72.24B | B- | ||
+3.10% | 59.84B | B | ||
+7.62% | 55.83B | A- | ||
+2.73% | 40.99B | C | ||
-3.04% | 35.26B | B | ||
-4.33% | 30.28B | B | ||
+73.69% | 22.68B | - | ||
+8.25% | 22.68B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock IBEX Limited - Nasdaq
- Ratings IBEX Limited